Clinical trial
A Phase 2 Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies
NCT02854436 is registered in ClinicalTrials.gov with Janssen Research & Development, LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies
- Lead sponsor
- Janssen Research & Development, LLC
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- August 31, 2016
- Completion date
- August 16, 2023
- Enrollment
- 289 (actual)
- Sites
- 110
Conditions
As the registry lists them; a condition with its own page is linked.